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ABSTRACT 
 
Background: Colorectal cancer is the third largest incidence of cancer in the world and is 
the third most common cause of death in women and men . Five-year overall survival (OS) 
in colorectal cancer who have undergone metastasis was 10 % . Hematologic toxicity may be 
a marker of biological activity of cytotoxic drug on various types of cancer . Neutropenia 
after chemotherapy known to be associated with increased patient survival . 
Objective : To establish whether chemotherapy-induced neutropenia is predictive of better 
outcome in patients with metastatic colorectal cancer (mCRC). 
Methods: This research was a case-control study. Subjects were patients with metastatic 
colorectal cancer in the Cancer Instalation Center  Tulip RSUP dr. Sardjito who meet the 
inclusion and exclusion criteria. Data were analyzed by bivariate analysis using chi square test 
and multivariate analysis with logistic regression.  
Results: Neutropenia present in 26 patients (32.5%) of the total 80 patients of the study. 
Neutropenia were significantly affect OS ( p = 0.001 and OR 7.73, 95%  CI: 2.51-23.80). 
Multivariate logistic regression analysis showed neutropenia and the number of metastases 
affect OS with p <0.001 and p <0.003. 
Conclusion: Neutropenia occurring during the two first lines of chemotherapy for 
metastases colorectal cancer  is  associated with better survival. Variables that affect OS is 
the number of metastases and incidence of neutropenia after chemotherapy. 
Keyword : Neutropenia, colorectal cancer, metastases, overall survival 
 
ABSTRAK 
 
Latar Belakang: Kanker kolorektal adalah kanker dengan insidensi terbesar ketiga di dunia dan 
merupakan penyebab kematian terbanyak ketiga pada wanita dan laki-laki.  Overall survival  lima tahun 
pada kanker kolorektal yang telah mengalami metastasis adalah sebesar 10%. Toksisitas hematologi dapat 
menjadi petanda aktivitas biologis terhadap obat sitostatika pada berbagai tipe kanker. Neutropenia pasca 
kemoterapi diketahui berhubungan dengan peningkatan survival pasien.  
Tujuan: Untuk mengetahui apakah  neutropenia yang diinduksi kemoterapi dapat menjadi prediktor 
outcome yang lebih baik pada kanker kolorektal metastasis  
Metode: Desain penelitian ini adalah kasus kontrol. Subyek penelitian adalah pasien kanker kolorektal 
metastasis di poliklinik Tulip RSUP dr. Sardjito Yogyakarta yang memenuhi kriteria inklusi dan 
eksklusi. Data penelitian diolah dengan analisa bivariat menggunakan Uji chi square dan analisa 
multivariat dengan uji regresi logistik.  
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Hasil Penelitian: Neutropenia terdapat pada 26 pasien (32.5%) dari total 80 pasien penelitian. 
Neutropenia mempengaruhi OS secara bermakna  dengan nilai p=0,001 dan OR 7.73 (IK95% 2.51-
23.80). Analisis multivariat dengan regresi logistik menunjukkan  neutropenia dan jumlah metastasis 
mempengaruhi OS dengan nilai p<0.001 dan p<0.003. 
Kesimpulan: Pasien dengan OS lebih dari 24 bulan dipengaruhi oleh kejadian neutropenia pasca 
kemoterapi lebih besar 7,73 kali dibandingkan pasien dengan OS kurang dari 24 bulan. Variabel yang 
mempengaruhi OS adalah jumlah metastasis dan kejadian neutropenia pasca kemoterapi. 
Kata Kunci : Neutropenia, kanker kolorektal, metastasis, overall survival 
 
 
INTRODUCTION 
Colorectal cancer is the third 
largest incidence of cancer in the world, 
with 1.4 million new cases diagnosed in 
2012. Colorectal cancer is the third most 
common  cause of death in women and 
men. 54% of cases of colorectal occur in 
developed countries, with the greatest 
incidence are in Europe, and the lowest 
incidence in Africa and Asia1. 
Overal Survivall (OS) colorectal 
cancer depends on the stage of disease 
when first diagnosed. Five years OS in 
colorectal cancer who have undergone 
metastasis was 10% 2. OS metastatic 
colorectal cancer patients who received 
supportive care only less than 6 month3. 
5-year survival for colorectal cancer at an 
advanced stage-regional and terminal 
decline of up to 70% and 12% 4. 
Various studies have reported 
that hematologic toxicity may be a marker 
of biological activity of the cytotoxic drug 
in various types kanker5. Another study 
systematic review and meta-analysis study 
conducted by Shitara et al6 in 13 studies 
of various types of cancer, showed 
leukopenia known to be associated with 
increased patient survival. 
This study aims to determine 
whether neutropenia after chemotherapy 
is prognostic and influence on Overall 
Survival in metastatic colorectal cancer 
patients at dr Sardjito Hospital. 
 
MATERIALS AND METHODS 
This research  uses a case-control 
study to determine the prognostic value 
of neutropenia after chemotherapy. The 
study was conducted at the Integrated 
Cancer Installation dr Sardjito Hospital  in 
the period January 2012 to December 
2015. The research sample in each case 
and control group are 40 patients, with a 
total sample of 80 patients. Metastatic 
colorectal cancer patients (mCRC) 
receiving chemotherapy in combination 
with bevacizumab were included in the 
study. Exclusion criteria were patients 
who had a history of other chronic 
diseases and medical records were 
incomplete 
Time recording starts at the 
beginning of patients diagnosed until the 
time of taking the data with 
accompanying patient information was 
alive or dead. Data management is done 
using the Statistical Package fo Social 
Science (SPSS) ver 13.0 To determine the 
relationship between independent 
variables with the OS performed bivariate 
analysis using chi-square test. The results 
of the bivariate analysis with p> 0,25 will 
be included in the multivariate analysis 
using logistic regression with 95% 
confidence intervals and significance 
accepted when p <0.05.  
To compare the survival in the 
group with no experience neutropenia and 
neutropenia after chemotherapy, survival 
analysis is then performed with a 
probability of survival was estimated by 
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the Kaplan-Meier method. Hazard Ratio 
(HR) and 95% CI were estimated using 
Cox regression analysis. 
This study was approved by 
ethics committees (Ethical clearance) of 
human biomedical research ethics 
committee of the Faculty of Medicine, 
University of Gadjah Mada, and the 
permission of the Director of dr. Sardjito. 
Hospital. 
 
RESULTS  
 
The research data showed 
research subjects male sex as many as 38 
people (47.5%) and female sex amounted 
to 42 (52.5%). Age of patients with 
colorectal cancer are in the productive 
age. Breakdown by age showed subjects 
who entered the group of young adults 
(18-40 years) of 8 patients (10%), middle 
age (41-65 years) of the 37 patients 
(46.25%), and elderly (> 65 years) by 33 
patients (41.25%). 
Metastasis to one organ occurred 
in 64 patients (80%) and multiple 
metastases occurred in 16 patients (20%). 
Hearts and lungs are the organs with the 
highest metastasis of 42 patients (52.5%) 
and 14 patients (17.5%). There are 
multiple metastases in 16 patients with 
lungs and the liver is the organ most 
frequently occur simultaneously and 
metastasis was found in 11 patients 
(13.75%). Type of adenocarcinoma 
histology type of cancer was found in 77 
patients (96.25%) and mucinous 
adenikarsinoma types found in 3 patients 
(3.75%). 
Neutropenia present in 26 
patients (32.5%) and as many as 54 
patients (67.5%) patients did not 
experience neutropenia. In the group with 
more than 24 months OS neutropenia 
occurred in 21 patients (26.25%) and 
neutropenia occurred as many as five 
patients (6:25%) in the OS in less than 24 
months. Grade 2 neutropenia occurred in 
22 (27.5%) patients and grade 3 
neutropenia found in 4 (5%) patients. 
 
Table 1. Patients Characteristics of Research Subjects with metastatic Colorectal cancer 
 
Variable 
 
N (%) 
 
Mean±S
D 
 
Median 
Overall survival 
≥24 
month 
<24 
month 
Gender Male 38(47.5)   20 18 
Female 42(52.5)   20 22 
Age <50 years old 25(31.25) 56.63±11
.13 
57.5 (28-
71) 
12 13 
>50 yearsold 55(68.75) 28 27 
Site metastases Tunggal 64 (80)   38 26 
1. Pulmo 
2. Hepar 
3. bone 
4. VU 
14 
42 
3 
5 
  10 
26 
1 
1 
4 
16 
2 
4 
Multiple 16(20)    2 14 
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1. lung dan liver 
2. Liver and bone 
3. Liver, lung, dan 
brain 
4. Liver dan VU 
11 
 
2 
 
1 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1 
 
0 
 
0 
10 
 
1 
 
1 
 
2     
Cancer histology adenokarsinoma 77(96.25)   39 38 
Adenikarsinoma 
mucinous 
3(3.75)   1 2 
 
Chemotherapy 
drug 
1. Xelox+bev 
2. Folfox+bev 
3. Folfiri+bev 
70(87.5) 
6(7.5) 
4(5) 
  36 
2 
2 
34 
4 
2 
Neutropenia Yes 
 Grade 2 
 Grade 3 
No 
26(32.5) 
22(27.5) 
4(5) 
54(67.5) 
 
 
 
 
21 
20 
1 
19 
5 
2 
3 
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Bivariat Analysis 
 
The results of the bivariate 
analysis neutropenia OS variables showed 
significant difference statistically between 
the two groups with p <0.001 and OR 
7.73 (IK95% 2.51-23.80) with probability 
neutropenia effect on OS was 89%.  
 
The bivariate analysis variable 
number of metastases to the OS showed 
significant difference p< 0.001 and OR 
10.23 (IK95% 2.14-48.84) with a 
probability number of metastases affect 
overall survival is of 91%. 
  
Table 2. Bivariate analysis of variables of age, sex, neutropenia, number of metastases and cancer 
histology on Overall Survival by chi-square test 
 
 Variable  
Overall survival  
OR 
(95%CI) 
 
P ≥24 month <24 month 
N % N % 
Age 
       <50years                                                                               
>50years 
  0.89 
(0.34-2.29) 
 
12 15 13 16.25 0,809 
28 35 27 33.75  
Jenis kelamin                             
       Male 
 
20 
 
25 
 
18 
 
22.5 
1.22 
(0.50-2.94) 
 
0,654 
       Female 20 25 22 27.5  
Neutropenia                          
       Yes 
       No 
 
21 
19 
 
26.25 
23.75 
 
5 
35 
 
6.25 
43.75 
7.73 
(2.51-23.80) 
 
0.001* 
Metastases 
       single 
       Multiple                             
 
  38      47.5 
   2         2.5 
 
  26      32.5 
  14      17.5 
10.23 
(2.14-48.84) 
 
0,001* 
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Cancer histology 
        Adenokarsinoma                                          
Adenokarsinoma 
musinous 
 
39 48.75
   1        1.25 
 
  38      47.5 
  2          2.5 
2.05 
(0.17-23.58) 
 
0.556 
* Statistically significant 
Multivariate analysis 
In the multivariate analysis used 
logistic regression with enter method, the 
independent variable has a value of p <25 
in the bivariate analysis, the variables 
neutropenia and number of metastases to 
the results presented in Table 3. 
 
 
 
 
Tabel 3. Multivariate analysis of variables neutropenia and the number of metastases to the OS with 
logistic regression test 
Variable P OR IK95% 
Neutropenia 0.001 10.43         2.79-40.04 
Metastasis  0.003 15.00 2.459-91.549 
 
Multivariate analysis showed the 
variables that affect the OS is neutropenia 
and number of metastases with p <0.001 
and p <0.003 .Power of the relationship 
from the largest to the smallest number of 
metastases (OR = 15,00) and neutropenia 
(OR = 10,43).  
 
DISCUSSION 
In this study, the mean age of 
patients was 57 years with an age range 28 
years to 71 years. In the study conducted 
Laurie et al7 mentions neutropenia and 
age is proven to affect the outcome of 
patients, but in the age of the study said 
influence the outcome of the patients 
were aged over 75 years. 
Neutropenia associated with 
overall survival significantly, which affects 
neutropenia independently, with p 
<0.0017. Mild leukopenia happens after 
chemotherapy is associated with better 
survival compared to the condition where 
no leukopenia or there are severe 
leukopenia after chemotherapy 
administration8. Neutropenia that occurs 
due to the use of optimal doses of drugs 
that affect the patients9. 
Hematological toxicity may 
reflect the biologic activity of cytotoxic 
drugs, while the absence of toxicity may 
indicate the dose of medication that is 
less, so that the necessary determination 
per individual dose of the drug that can 
lower toxicity and improve drugs 
efficacy10. Oxaliplatin known to have a 
suppressive effect on the bone marrow at 
specific doses11. In this study, there were 
76 patients (95%) received chemotherapy 
oxaliplatin at a dose of 130 mg/m², which 
is based on research Tournigand et al., 
(2004) dose could trigger myelotoxicity in 
the amount of 85-135 mg/m2 
intravenously with neutropenia of grade 3 
and 4 frequent and the incidence of 
febrile neutopenia only by 4%. However, 
only 24 patients (31.5%) experienced 
neutropenia after chemotherapy. 
According Delord et al12, this was due to 
oxaliplatin plasma clearance is not only 
based on body surface area only, but will 
also be affected by factors of age, sex, and 
serum creatinine. The results of this study 
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complements several studies conducted in 
other cancer types that have reached the 
stage of metastasis. According to Wei et 
al5, hematologic toxicity may be a marker 
of biological activity of drug sitostatica on 
various types of cancer. In various studies 
say, neutropenia is a known prognostic 
factor for patient survival is better in 
patients with lung cancer, gastric cancer, 
or ovarian cancer who have undergone 
metastasis13, and in breast cancer or 
esophageal cancer therapy neoajuvan14. 
 
CONCLUSIONS AND 
RECOMMENDATIONS 
 
Patients with more than 24 months OS 
influenced by post-chemotherapy 
neutropenia incidence of 7.73 times 
greater than patients with OS less than 24 
months with the probability of 
neutropenia affect OS by 89%. Variables 
that affect the OS is the number of 
metastases and neutropenia, with the 
strength of the relationship of the largest 
is the number of metastasis (OR = 15.00) 
and neutropenia (OR = 10.43). The 
results of this study can be used as one of 
the new clinical evidence regarding the 
role of neutropenia in determining the 
prognosis at the time of initial 
chemotherapy in patients with mCRC in 
clinical practice. Cohort studies need to be 
conducted with a sample of the research 
with post-chemotherapy neutropenia were 
more in the group tested, so that research 
results obtained have a level of evidence 
better. 
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